• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Clinical Trial for Symptomatic Neurogenic Orthostatic Hypotension

Zebra

Zebra

Senior Member
Messages
866
Location
Northern California
Hi, Phoenix Risers!

I was on the UT Southwest Medical Center (Dallas, TX) website today, and I came across a clinical trial that I thought may be of interest to some of you.

I'll try to post a link here, but you will have to go to the Clinical Trials website to see full details, contact info, and eligibility requirements.

Clinical Effect of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure
Description:A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and snOH with up to 4 weeks of treatment.
Contact(s):Call 214-648-5005
studyfinder@utsouthwestern.edu
Principal Investigator: Meredith Bryarly
Principal Investigator ID: 126795
Gender: All
Age: 30 Years and over
Phase: Phase 3
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: NCT03750552
IRB Number: STU-2018-0337

https://clinicaltrials.utswmed.org/studies?page=2&search[category]=14
 
You must log in or register to reply here.